Literature DB >> 8644655

Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.

J Lefkovits1, R J Ivanhoe, R M Califf, B A Bergelson, K M Anderson, G L Stoner, H F Weisman, E J Topol.   

Abstract

Percutaneous transluminal coronary angioplasty (PTCA) for acute myocardial infarction is an attractive alternative to thrombolysis, but is still limited by recurrent ischemia and restenosis. We determined whether adjunctive platelet glycoprotein IIb/IIIa receptor blockade improved outcomes in patients undergoing direct and rescue PTCA in the Evaluation of c7E3 for Prevention of Ischemic Complications (EPIC) trial. Of the 2,099 patients undergoing percutaneous intervention who randomly received chimeric 7E3 Fab (c7E3) as a bolus, a bolus and 12-hour infusion, or placebo, 42 underwent direct PTCA for acute myocardial infarction and 22 patients had rescue PTCA after failed thrombolysis. The primary composite end point comprised death, reinfarction, repeat intervention, or bypass surgery. Outcomes were assessed at 30 days and 6 months. Baseline characteristics were similar in direct and rescue PTCA patients. Pooling the 2 groups, c7E3 bolus and infusion reduced the primary composite end point by 83% (26.1% placebo vs 4.5% c7E3 bolus and infusion, p = 0.06). No reinfarctions or repeat urgent interventions occurred in c7E3 bolus and infusion patients at 30 days, although there was a trend toward more deaths in c7E3-treated patients. Major bleeding was increased with c7E3 (24% vs 13%, p = 0.28). At 6 months, ischemic events were reduced from 47.8% with placebo to 4.5% with c7E3 bolus and infusion (p = 0.002), particularly reinfarction (p = 0.05) and repeat revascularization (p = 0.002). We conclude that adjunctive c7E3 therapy during direct and rescue PTCA decreased acute ischemic events and clinical restenosis in the EPIC trial. These data provide initial evidence of benefit for glycoprotein IIb/IIIa receptor blockade during PTCA for acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8644655     DOI: 10.1016/s0002-9149(96)00128-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  18 in total

Review 1.  Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors.

Authors:  M T Roe; D J Moliterno
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 2.  Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors.

Authors:  F H Jafary; C D Kimmelstiel
Journal:  J Thromb Thrombolysis       Date:  2000-02       Impact factor: 2.300

Review 3.  Glycoprotein IIb/IIIa Inhibition as an adjunct to rescue angioplasty after failed fibrinolysis.

Authors:  J A Sallach; A B Greenbaum
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 4.  Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations.

Authors:  William S Weintraub; Leonid Mandel; Sandra A Weiss
Journal:  Pharmacoeconomics       Date:  2013-11       Impact factor: 4.981

Review 5.  A risk-benefit assessment of abciximab in angioplasty.

Authors:  N S Kleiman
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

6.  Association of glycoprotein IIb/IIIa inhibitors and long-term survival following administration during percutaneous coronary intervention for acute myocardial infarction.

Authors:  Jeffrey S Berger; David L Brown
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 7.  [Therapy of acute myocardial infarct--primary PTCA or thrombolysis?].

Authors:  A Vogt; K L Neuhaus
Journal:  Herz       Date:  1999-08       Impact factor: 1.443

8.  Hospital transfer for primary coronary angioplasty in high risk patients with acute myocardial infarction.

Authors:  E Straumann; S Yoon; B Naegeli; J Frielingsdorf; A Gerber; E Schuiki; O Bertel
Journal:  Heart       Date:  1999-10       Impact factor: 5.994

Review 9.  Cardiopulmonary bypass in patients with pre-existing coagulopathy.

Authors:  William DeBois; Junli Liu; Leonard Lee; Leonard Girardi; Wilson Ko; Anthony Tortolani; Karl Krieger; O Wayne Isom
Journal:  J Extra Corpor Technol       Date:  2005-03

Review 10.  Abciximab. An updated review of its use in ischaemic heart disease.

Authors:  R H Foster; L R Wiseman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.